



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/518,815	First Named Inventor: Bailey
371 Filing Date: December 20, 2004	Attorney Docket No.: 100729-1P US
Examiner: Mark L. Berch	Group Art Unit : 1624
Customer No.: 22466	Confirmation No.: 8233
Title: Novel Purine –or Pyrrolol [2,3-d]pyrimidine-2-carbonitiles for Treating Diseases Associated with Cysteine Protease Activity	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

Applicants would like to bring to the Examiner's attention that cited reference EP 1724264 (foreign reference no. 6) is the English equivalent of cited reference WO 2005085210 (foreign reference no. 4).

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

(1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or

(2) after the period defined in (1) but before the mailing date of a **final Action** or a **Notice of Allowance** under 37 C.F.R. 1.311, and

- the requisite Statement is below, **OR**
- the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00** to deposit account No. 26-0166, referencing Attorney Docket No. 100729-1p us, or

(3) after the mailing date of a **final Action** or **Notice of Allowance** but before the payment of the **Issue Fee**, **AND**

- the requisite Statement is below, **AND**
- the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00** to deposit account No. , referencing Attorney Docket No. , or

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Respectfully submitted,
/Jianzhong SHEN, Reg.#48076/

Name: Jianzhong Shen
Dated: August 2, 2007
Reg. No.: 48,076
Phone No.: 302-886-8854